Consun Pharmaceutical Group Limited (FRA:C1P)

Germany flag Germany · Delayed Price · Currency is EUR
1.190
+0.260 (27.96%)
Last updated: May 13, 2025
91.94%
Market Cap 904.09M
Revenue (ttm) 392.66M
Net Income (ttm) 120.48M
Shares Out n/a
EPS (ttm) 0.14
PE Ratio 7.50
Forward PE 7.00
Dividend 0.11 (11.24%)
Ex-Dividend Date Jun 10, 2025
Volume n/a
Average Volume 63
Open 0.935
Previous Close 0.930
Day's Range 0.935 - 1.190
52-Week Range 0.071 - 1.200
Beta n/a
RSI 63.84
Earnings Date May 21, 2025

About FRA:C1P

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 3,164
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol C1P
Full Company Profile

Financial Performance

In 2024, FRA:C1P's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.